Literature DB >> 21275973

Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.

Ellen R McPhail, Mark E Law, Paul A Decker, Brian P O'Neill.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21275973      PMCID： PMC3438891          DOI： 10.1111/j.1365-2141.2010.08564.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the North Central Cancer Treatment Group (NCCTG) Study 86-72-52.

Authors:  B P O'Neill; C H Wang; J R O'Fallon; J D Colgan; J D Earle; R L Krigel; L D Brown; W L McGinnis
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

2.  Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.

Authors:  Linfeng Chen; Przemyslaw Juszczynski; Kunihiko Takeyama; Ricardo C T Aguiar; Margaret A Shipp
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

Review 3.  Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.

Authors:  Samson T Jacob; Tasneem Motiwala
Journal:  Cancer Gene Ther       Date:  2005-08       Impact factor: 5.987

4.  Receptor-type protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor function.

Authors:  Yiru Xu; Li-Jun Tan; Vladimir Grachtchouk; John J Voorhees; Gary J Fisher
Journal:  J Biol Chem       Date:  2005-10-31       Impact factor: 5.157

5.  CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma.

Authors:  Nadia N Laack; Brian Patrick O'Neill; Karla V Ballman; Judith Rich O'Fallon; Xiomara W Carrero; Paul J Kurtin; Bernd W Scheithauer; Paul D Brown; Thomas M Habermann; Joseph P Colgan; Mark R Gilbert; Roland B Hawkins; Roscoe F Morton; Harry E Windschitl; Tom R Fitch; Eduardo R Pajon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-26       Impact factor: 7.038

6.  Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas.

Authors:  Mitsutoshi Nakamura; Munehiro Kishi; Toshisuke Sakaki; Hiroyuki Hashimoto; Hiroyuki Nakase; Keiji Shimada; Eiwa Ishida; Noboru Konishi
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

7.  Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.

Authors:  Nadia N Laack; Karla V Ballman; Paul B Brown; Brian Patrick O'Neill
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-01       Impact factor: 7.038

Review 8.  Primary central nervous system lymphoma.

Authors:  Andrés J M Ferreri; Michele Reni
Journal:  Crit Rev Oncol Hematol       Date:  2007-06-21       Impact factor: 6.312

9.  Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course.

Authors:  Francois M Cady; Brian Patrick O'Neill; Mark E Law; Paul A Decker; David M Kurtz; Caterina Giannini; Alyx B Porter; Paul J Kurtin; Patrick B Johnston; Ahmet Dogan; Ellen D Remstein
Journal:  J Clin Oncol       Date:  2008-07-21       Impact factor: 44.544

10.  Genome-wide review of transcriptional complexity in mouse protein kinases and phosphatases.

Authors:  Alistair R R Forrest; Darrin F Taylor; Mark L Crowe; Alistair M Chalk; Nic J Waddell; Gabriel Kolle; Geoffrey J Faulkner; Rimantas Kodzius; Shintaro Katayama; Christine Wells; Chikatoshi Kai; Jun Kawai; Piero Carninci; Yoshihide Hayashizaki; Sean M Grimmond
Journal:  Genome Biol       Date:  2006-01-26       Impact factor: 13.583
  10 in total
  1 in total

Review 1.  Primary CNS lymphoma.

Authors:  Elizabeth H Phillips; Christopher P Fox; Kate Cwynarski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.